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Previous studies have shown the pineal hormone melatonin 
to influence mammalian coat color and amphibian skin color 
when administered exogenously. It has also been suggested 
that melatonin can be employed effectively to inhibit pro-
gress of neoplastic disease in both animals and humans. In the 
present study, we set out to investigate the effect of melato-
nin on human skin color in an effort to uncover its mecha-
nism of action as an antimelanoma agent. We followed seven 
patients receiving orally administered melatonin over a mean 
duration of 19 months, and four controls who were not re-
ceiving melatonin, for an average of 12 months using 
T he role of the pineal hormone melatonin (N-acetyl-5-methoxytryptamine) in human physiology has been the subject of much investigation in recent years. Melatonin production in humans, as in photoperiodic species, is regulated by a circadian rhythm syncron-
ized to the light/dark cycle, but the degree of similarity in its human 
and non-human physiologic roles is less clear [1,2]. In photope-
riodic species, for instance, melatonin is believed to regulate neuro-
endocrine processes such as reproductive cycles, seasonal pelage 
change, and metabolism [3,4] . In humans, however, aside from 
demonstrated correlations between serum melatonin levels and 
menstrual cycle, season, and age, specific neuroendocrine functions 
of melatonin have yet to be proven conclusively [5 - 8]. 
Among the more interesting potential clinical applications of 
melatonin is as an antitumor agent, and this is one of the primary 
areas of current melatonin research. Melatonin has been demon-
strated to inhibit B16 melanoma growth in athymic mice [9], and 
several human cancer cell lines in vitro [10,11]. We recently re-
ported a moderate antitumor effect in patients with metastatic ma-
lignant melanoma treated with oral melatonin [12]. 
In certain animals, melatonin inhibits melanin dispersion and 
consequent skin darkening [13]' apparently by decreasing cyclic 
adenosine monophosphate (cAMP) production under the influence 
of melanocyte stimulating hormone (MSH) [14]. On the basis of the 
data supporting a role for melatonin in determining skin color in 
photoperiodic species, we undertook an investigation of the long-
term effects of oral melatonin on human skin color. 
MATERIALS AND METHODS 
Skin Color Measurement Skin color was measured with a Photovolt 
model 577 digital reflection and gloss meter (Photovolt, Indianapolis, IN) 
using tristimulus filters mounted on a revolving turret. Filters transmitting 
three narrow bands of visible radiation were employed: tri-blue (peak B, 440 
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monthly reflectometry measurements in three sites to deter-
mine skin color. There was no significant change in skin 
color among patients receiving melatonin, and no difference 
relative to controls. On the basis of these data, we conclude 
that melatonin has no effect on human skin pigmentation, 
and that the demonstrated effectiveness of melatonin in me-
diating malignant melanoma growth is not related to sup_ 
pression of normal melanogenesis. Key words: malignant mela-
noma/pigmentation/skin rej1ectometry. ] Invest Dermatol 102: 
258 - 259,1994 
nm; B range, 410-490 nm), tri-green (peak G, 550 nm; Grange, 450-620 
nm), and tri-amber (peak A, 590 nm; A range, 540-660 nm) . After zeroing 
the instrument with a black cavity zero standard, and calibrating each of the 
three wavelength filters to the appropriate value against a standard reflection 
plate, three locations were irradiated based on varying degrees of sun expo_ 
sure: the center of the glabella ("head"), the medial upper right arm ("arm") 
and the tip of the right scapula ("back"). Two measurements with each 
wavelength radiation were made at each location, then averaged. From these 
values a simple mean reflectance was calculated (24). Seven patients with 
metastatic malignant melanoma who were receiving daily doses of oral 
melatonin and four patient spouses were studied after written informed 
consent was obtained. Two patients each received doses of 50 and 700 
mg/m2/d, and one each received 5, 25, and 150 mg/m2/d. None of the 
patients or controls had known metabolic disease or disorders of skin pig-
mentation. Skin color measurements were made approximately once a 
month. 
Melatonin Melatonin (Regis Chemical Company, Chicago, IL) was pre-
pared in capsule form by the University of Colorado Pharmacy. It Was 
suppl~ed to patients in ~mber containers to protect it from light, and they 
were mstructed to store It refngerated. Melatonin was administered orally in 
four divided doses per day. 
RESULTS AND DISCUSSION 
N~ long-term st.udies of the effect of melatonin on human pigmen-
tation have prevIOusly been reported. The single patient reported by 
Nordlund and Lerner [15] to have developed decreasing pigmenta-
tion after a 30-day administration of high-dose oral melatonin was a 
patient with adrenal hyperplasia in whom there was presumed ex-
cessive secretion of MSH. No such patients were included in the 
present study, and our data do not suggest that under normal cir-
cumstances melatonin decreases human pigmentation. 
In the present study, we measured skin reflectance in sun-exposed 
and non-sun-exposed areas to determine, if changes were found 
whether they might be related to MSH effects. We assumed tha~ 
pigmentation of the ~orehead would be partially mediated by MSH, 
and that we would witness the major effect of melatonin in this area. 
The present data, however, have not shown prolonged ingestion of 
melatonin to have any effect on any site. 
Figure 1 shows the mean changes in skin color over time of the 
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Figure 1. Mean skin color change (per~e~t reflectance) over time in seven 
patients with malIgnant melanoma receiving dally oral melatonin. 
seven melanoma subjects (note: higher reflectance correlates with 
lighter skin). Initially there appeared to be a slight decrease in skin 
reflectance over time, but this was not statistically significant (p > 
0.05). In patients treated with melatonin there was an increase in 
mean skin reflectance on the head 0.40/0 (range, - 4.2-1.30/0; SD, 
1. 7%), and a mean decrease of2.1 % (range, - 5.4-1.90/0; SD, 1.90/0) 
on the arm. On the back, reflectance changes ranged from - 4.1 to 
2.5%, with a mean increase of 0.20/0 and a standard deviation of 
2.3%. There was no significant difference in skin color in patients or 
controls over the study period. Because skin reflectance values for 
shorter wavelength light can be influenced by blood hemoglobin 
and degree of oxygenation [16], we also looked at tri-amber reflec-
tance values, which may be more accurate indicators of skin color as 
determined by melanin content [1 7] . However, there was no signif-
icant difference between average and tri-amber reflectance over 
time (p > 0.05). 
Table I shows the actual figures and the dose levels of melatonin 
for the individual patients. N o dose-response pattern was observed. 
It can be seen that although there was considerable variation among 
individual patients and specific reflectance locations, the skin color 
of four patients for whom we were able to fo llow spouse controls 
fluctuated similarly. 
Our primary research interest has been in the potential role of 
melatonin in the therapy of humans with advanced malignant mel-
anoma. In previous in vitro studies and in animal systems, melatonin 
has demonstrated an ability to suppress melanoma cell growth 
under certain circumstances [9,11]. In a separate study, we have 
shown that 160/0 of 40 human patients with metastatic malignant 
melanoma who were treated with oral melatonin had partial regres-
sion or stabilization of their disease [12]. Whereas this response rate 
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is low, any therapeutic benefit in malignant melanoma is of interest. 
The present data suggest that the previous anti-melanoma effect we 
observed was not due to suppression of melanogenesis, as measured 
by skin reflectometry. 
Cutaneous pigmentation in humans does not appear to be regu-
lated in any significant fashion by the pineal-derived hormone mel-
atonin. Oral adminis tration for prolonged periods of time, as dem-
onstrated here, has not resulted in any significant alteration. 
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Table I. Total and Mean Monthly Change in Skin Color in Seven Patients with Malignant Melanoma Receiving Daily Oral Melatonin 
Time on Total ~ in % Reflectance Mean Monthly ~ in % Reflectance 
Dose Level Melatonin 
Patient (mgjm2jd) (months) Head Arm Back Head Arm Back 
1 5 5 0.9 -3.6 0.8 0.19 - 0.72 0.16 
2 25 19 1.3 -4.0 1.2 0.07 -0.21 0.06 
3 50 21 004 1.9 2.0 0.02 0.09 0.10 
4 50 26 - 2.5 -2.0 2.5 - 0.10 - 0.08 0.10 
5 150 32 0.3 -SA - 4.1 0.01 -0.17 -0.13 
6 700 26 1.2 0.0 2.5 0.05 0.0 0.10 
7 700 5 -4.2 -1.9 -3.3 -0.84 -0.39 -0.67 
Mean 19 -004 -2.1 0.2 - 0.02 -0.11 0.D1 
SD 8.1 1.7 1.9 2.3 0.20 0.20 0.20 
